About BioHelix
BioHelix is a Healthcare company based in Beverly (United States) founded in 2004, and was acquired by Quidel in May 2013. Novel molecular diagnostics are developed using isothermal amplification technologies. The company has 22 employees. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its legal entity is BioHelix Corporation. Its competitors include Inflammatix, Karius and Visby Medical; 3 of its 3 listed competitors have raised funding.
Company details
Biohelix, a spin-off from New England Biolabs, develops novel molecular diagnostic and research solutions using isothermal amplification technologies. It has a suite of proprietary technologies, including helicase-dependent amplification (HDA) using isothermal PCR, amplification technologies, and technology for whole-genome amplification that has been licensed from Harvard. Clinical diagnostic products include the instrument-free IsoAmp range of molecular assays for infectious diseases such as Bordetella, C. difficile, Group A and B Streptococcus, herpes (both HSV 1 2) and Trichomonas, as well as products for the detection of genetic diseases such as hereditary hemochromatosis and factor V Leiden. In addition, the company also specialized in life science research products such as the IsoAmp range of amplification kits for PCR, the PrimeNavigator series of extremely thermostable single-stranded DNA binding proteins, and thermostable mesophilic DNA helicases. In May 2013, Quidel acquired Biohelix for 10M upfront plus additional milestone payments.
- Headquarters Beverly, United States
- Employees 22
- Stage Acquired
- SectorsHealthcare
- Website biohelix.com
- Social LinkedIn
- Acquired by Quidel (May 2013)
- Legal Name Biohelix Corporation
Funding Insights of BioHelix
- Total Rounds 4
- Last Round Grant — $805,716
- First Round $143,606
(Feb 2009)
- Investors Count 1
All 4 funding rounds of BioHelix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in BioHelix
BioHelix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and QuidelOrtho.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
QuidelOrtho is engaged in providing diagnostic testing solutions globally. | quidel.com | San Diego, United States |
Investor details for BioHelix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioHelix
4 dated milestones of BioHelix across 9 years, from founding to its latest funding, stage changes and deals.
- Founded BioHelix is founded.
- Funding First funding round of $144K.
- Funding Latest funding round, Grant, of $806K.
- Exit Acquired by Quidel.
Competitors of BioHelix
BioHelix has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Karius and Visby Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. |
Detailed competitors of BioHelix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BioHelix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioHelix
BioHelix was founded in 2004 and raised its 1st funding round 5 years after it was founded.
BioHelix is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.
BioHelix has 22 employees.
Biohelix, a spin-off from New England Biolabs, develops novel molecular diagnostic and research solutions using isothermal amplification technologies. It has a suite of proprietary technologies, including helicase-dependent amplification (HDA) using isothermal PCR, amplification technologies, and technology for whole-genome amplification that has been licensed from Harvard. Clinical diagnostic products include the instrument-free IsoAmp range of molecular assays for infectious diseases such as Bordetella, C. difficile, Group A and B Streptococcus, herpes (both HSV 1 2) and Trichomonas, as well as products for the detection of genetic diseases such as hereditary hemochromatosis and factor V Leiden. In addition, the company also specialized in life science research products such as the IsoAmp range of amplification kits for PCR, the PrimeNavigator series of extremely thermostable single-stranded DNA binding proteins, and thermostable mesophilic DNA helicases. In May 2013, Quidel acquired Biohelix for 10M upfront plus additional milestone payments.
BioHelix's top competitors include Visby Medical, Inflammatix and Karius.
BioHelix has 2 investors. Key investors include HHS, and QuidelOrtho.
BioHelix operates through Biohelix Corporation.
Yes. BioHelix was acquired by Quidel in May 2013.